Max Planck Institute 
Welcome,         Profile    Billing    Logout  
 3 Products   155 Diseases  3 Products   3 Trials   276 News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
recombinant human erythropoietin / Max Planck Institute, Pfizer
2008-000453-35: Open-label phase IIa pilot study exploring safety and potential efficacy of recombinant human erythropoietin in early mild Alzheimer Dementia and therapy-refractory Major Depression (“EPO-AD”)

Ongoing
2
20
Europe
Erypo, Erypo
Max-Planck-Institute of Experimental Medicine
Early, mild dementia of the Alzheimer’s Type and therapy-refractory Major Depression
 
 
VPM1002 / SAKK, Serum Institute of India
NCT04387409 / 2020-001376-15: Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic

Active, not recruiting
3
59
Europe
VPM1002, Placebo
Vakzine Projekt Management GmbH, FGK Clinical Research GmbH
Infection, Respiratory Tract
05/21
05/21
VPM1002, NCT04351685: Evaluation of Efficacy and Safety of in Comparison to BCG in Prevention of Tb Infection in Infants

Completed
3
6940
RoW
VPM1002, BCG SII
Serum Institute of India Pvt. Ltd., Vakzine Projekt Management GmbH
Mycobacterium Tuberculosis Infection
10/24
10/24
NCT03152903: Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence

Completed
2/3
2000
RoW
VPM1002 (Recombinant BCG Vaccine), Placebo
Serum Institute of India Pvt. Ltd.
Prevention of TB Recurrence
12/23
12/23
SAKK 06/19, NCT04630730: Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Active, not recruiting
2
46
Europe
Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC), VPM1002BC, Atezolizumab, Tecentriq™, Cisplatin, Platinol®, Gemcitabine, Gemzar ®
Swiss Group for Clinical Cancer Research
Bladder Cancer
06/26
06/30
SAKK 06/14, NCT02371447 / 2014-005330-58: VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer

Completed
1/2
39
Europe
VPM1002BC, Mycobacterium bovis BCG∆ureC::Hly+, VPM1002
Swiss Group for Clinical Cancer Research
Bladder Cancer
10/19
03/23
NCT05539989: Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa

Withdrawn
1/2
480
RoW
VPM1002 Vaccine, BCG Vaccine, Placebo
International Maternal Pediatric Adolescent AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH)
Tuberculosis, HIV Infections
07/27
07/27
TMV-018 / Merck (MSD), Max Planck Institute
2019-003550-88: A Phase I/II dose-escalation trial investigating the oncolytic virus TMV-018 in combination with a chemotherapy precursor (5-Fluorocytosine) or an immunotherapeutic agent (anti-PD-1 therapy) in patients with tumors of the gastrointestinal tract in terms of safety, clinical activity as well as pharmacokinetics and pharmacodynamics.

Not yet recruiting
1/2
39
Europe
TMV-018, TMV-018, Solution for infusion
Themis Bioscience GmbH, Themis Biosience GmbH
Patients with histologically confirmed diagnosis of colorectal carcinoma (left-sided or rectal), esophageal carcinoma, or gastric cancer., Patients with histologically confirmed diagnosis of colorectal carcinoma (left-sided or rectal), esophageal carcinoma, or gastric cancer., Diseases [C] - Cancer [C04]
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
recombinant human erythropoietin / Max Planck Institute, Pfizer
2008-000453-35: Open-label phase IIa pilot study exploring safety and potential efficacy of recombinant human erythropoietin in early mild Alzheimer Dementia and therapy-refractory Major Depression (“EPO-AD”)

Ongoing
2
20
Europe
Erypo, Erypo
Max-Planck-Institute of Experimental Medicine
Early, mild dementia of the Alzheimer’s Type and therapy-refractory Major Depression
 
 
VPM1002 / SAKK, Serum Institute of India
NCT04387409 / 2020-001376-15: Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic

Active, not recruiting
3
59
Europe
VPM1002, Placebo
Vakzine Projekt Management GmbH, FGK Clinical Research GmbH
Infection, Respiratory Tract
05/21
05/21
VPM1002, NCT04351685: Evaluation of Efficacy and Safety of in Comparison to BCG in Prevention of Tb Infection in Infants

Completed
3
6940
RoW
VPM1002, BCG SII
Serum Institute of India Pvt. Ltd., Vakzine Projekt Management GmbH
Mycobacterium Tuberculosis Infection
10/24
10/24
NCT03152903: Study to Check the Efficacy and Safety of Recombinant BCG Vaccine in Prevention of TB Recurrence

Completed
2/3
2000
RoW
VPM1002 (Recombinant BCG Vaccine), Placebo
Serum Institute of India Pvt. Ltd.
Prevention of TB Recurrence
12/23
12/23
SAKK 06/19, NCT04630730: Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC

Active, not recruiting
2
46
Europe
Recombinant intravesical BCG (Bacillus Calmette-Guérin VPM1002BC), VPM1002BC, Atezolizumab, Tecentriq™, Cisplatin, Platinol®, Gemcitabine, Gemzar ®
Swiss Group for Clinical Cancer Research
Bladder Cancer
06/26
06/30
SAKK 06/14, NCT02371447 / 2014-005330-58: VPM1002BC in Recurrent Non-muscle Invasive Bladder Cancer

Completed
1/2
39
Europe
VPM1002BC, Mycobacterium bovis BCG∆ureC::Hly+, VPM1002
Swiss Group for Clinical Cancer Research
Bladder Cancer
10/19
03/23
NCT05539989: Safety and Immunogenicity of VPM1002 Vaccination or BCG Revaccination Against TB in Pre-Adolescents Living With and Without HIV in South Africa

Withdrawn
1/2
480
RoW
VPM1002 Vaccine, BCG Vaccine, Placebo
International Maternal Pediatric Adolescent AIDS Clinical Trials Group, National Institute of Allergy and Infectious Diseases (NIAID), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH)
Tuberculosis, HIV Infections
07/27
07/27
TMV-018 / Merck (MSD), Max Planck Institute
2019-003550-88: A Phase I/II dose-escalation trial investigating the oncolytic virus TMV-018 in combination with a chemotherapy precursor (5-Fluorocytosine) or an immunotherapeutic agent (anti-PD-1 therapy) in patients with tumors of the gastrointestinal tract in terms of safety, clinical activity as well as pharmacokinetics and pharmacodynamics.

Not yet recruiting
1/2
39
Europe
TMV-018, TMV-018, Solution for infusion
Themis Bioscience GmbH, Themis Biosience GmbH
Patients with histologically confirmed diagnosis of colorectal carcinoma (left-sided or rectal), esophageal carcinoma, or gastric cancer., Patients with histologically confirmed diagnosis of colorectal carcinoma (left-sided or rectal), esophageal carcinoma, or gastric cancer., Diseases [C] - Cancer [C04]
 
 

Download Options